Wells Fargo & Company Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by equities research analysts at Wells Fargo & Company from $235.00 to $250.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the specialty pharmaceutical company’s stock. Wells Fargo & Company‘s target price points to a potential upside of 30.45% from the stock’s previous close.

A number of other research analysts have also commented on JAZZ. Truist Financial upped their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 29th. Needham & Company LLC raised their price target on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Bank of America lifted their price target on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Wall Street Zen upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Fourteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $208.60.

Jazz Pharmaceuticals Trading Up 10.2%

Shares of NASDAQ:JAZZ traded up $17.81 during midday trading on Wednesday, hitting $191.64. 1,912,962 shares of the stock traded hands, compared to its average volume of 1,029,824. The stock has a market capitalization of $11.64 billion, a PE ratio of -31.32, a P/E/G ratio of 0.93 and a beta of 0.26. The business’s 50 day moving average is $168.08 and its two-hundred day moving average is $150.27. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09. Jazz Pharmaceuticals has a one year low of $95.49 and a one year high of $194.83.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 4,660 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $171.20, for a total transaction of $797,792.00. Following the completion of the transaction, the chief accounting officer directly owned 7,012 shares of the company’s stock, valued at $1,200,454.40. This trade represents a 39.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the business’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total transaction of $379,363.38. Following the sale, the senior vice president directly owned 19,508 shares in the company, valued at $3,306,801.08. The trade was a 10.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Cardinal Capital Management boosted its position in shares of Jazz Pharmaceuticals by 0.5% in the 4th quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock worth $2,471,000 after purchasing an additional 66 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in Jazz Pharmaceuticals by 9.0% during the third quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 81 shares during the last quarter. UMB Bank n.a. boosted its holdings in Jazz Pharmaceuticals by 12.6% in the fourth quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 81 shares in the last quarter. Tectonic Advisors LLC grew its stake in shares of Jazz Pharmaceuticals by 1.5% in the third quarter. Tectonic Advisors LLC now owns 5,626 shares of the specialty pharmaceutical company’s stock worth $742,000 after acquiring an additional 82 shares during the last quarter. Finally, Pinnacle Associates Ltd. increased its holdings in shares of Jazz Pharmaceuticals by 0.7% during the fourth quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock valued at $1,905,000 after acquiring an additional 83 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Key Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q4 beat — Jazz reported Q4 revenue of $1.20B and EPS of $6.64, both topping Street estimates, and closed 2025 with record total revenues of $4.3B. Press Release
• Positive Sentiment: Product momentum — Management highlighted strong commercial performance: Xywav reached $1.7B (+12% YoY), Epidiolex $1.1B (+9% YoY) and Modeyso delivered $37M in its first full quarter, supporting top-line growth. Product Highlights
• Positive Sentiment: 2026 revenue guide — Jazz issued 2026 total revenue guidance of $4.25B–$4.50B and management reiterated progress on rare-disease and oncology launches (including an expected sBLA RTOR filing for zanidatamab). This outlook is a near-term catalyst. Revenue Outlook
• Positive Sentiment: Analyst upgrade — Bank of America raised its price target to $275 and reiterated a Buy rating, signaling significant analyst upside versus current levels and likely supporting investor demand. Benzinga
• Neutral Sentiment: Investor materials posted — The full earnings call transcript and the Q4 slide deck are available for review (useful for modeling product/launch assumptions and margin drivers). Earnings Transcript Presentation
• Neutral Sentiment: Street analysis — Coverage pieces (Zacks, Seeking Alpha previews) compare metrics to estimates and highlight what to watch (oncology launches, sBLA timing) — useful but not new surprises. Zacks Analysis
• Negative Sentiment: Margin and profitability notes — Despite the beat, some filings/coverage flag a negative net margin (reported -8.86% in the quarter) and other accounting/expense dynamics that could pressure reported profitability or require clarification from management. MarketBeat Earnings Summary

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.